Primary Meibomian Gland Carcinomas: a Technical Challenge to Treat from Radiotherapist Perspective

Case Report

Austin J Clin Case Rep. 2014;1(3): 1015.

Primary Meibomian Gland Carcinomas: a Technical Challenge to Treat from Radiotherapist Perspective

Rakesh Kapoor*

Department of Radiation Oncology, Institute of Medical Education and Research, India

*Corresponding author: Rakesh Kapoor, Department of Radiation Oncology, Institute of Medical Education and Research, Chandigarh, India

Received: May 20, 2014; Accepted: June 12, 2014; Published: June 16, 2014

Summary

Meibomian gland carcinoma is a very rare malignancy which we commonly deal with. Because of its slow growing nature and its ability to masquerade as multiple benign conditions treating this tumour is a major therapeutic challenge from an oncologist perspective. Here we have shared our experience with three such cases.

Background

The sebaceous carcinoma is a very rare malignant neoplasm primarily found in the area of the eyelid. Most of these cases originate in the tarsal meibomian glands. Meibomian gland carcinoma is considered to be the second most common eyelid malignancy after basal cell carcinoma [1]. These tumours are slow growing which may initially look benign in appearance and simulates to a number of benign pathological conditions like chalazion, papilloma, seborrheic keratitis, keratoacanthoma etc. A delay in diagnosis, which can be attributed primarily to ability of this tumour to masquerade as more benign conditions, often leads to inappropriate management with increased morbidity and mortality rates. Here we describe three cases of primary meibomian gland carcinoma with different biological behavior and management.

Case summary I

A 45 year old male patient presented with redness and watering of left eye for two months, painless progressive swelling of left eyelid since one month and mild decrease in vision in left eye for the same duration. On clinical examination a firm lobular pinkish mass was felt in the left lower eyelid involving bulbar conjunctiva. He underwent computed tomography of orbit which showed an enhancing mass lesion measuring 3.7x2.8x2.2 cm seen in inferolateral part of left orbit having ill defined fat planes with lateral rectus and inferior rectus muscles causing proptosis. PET-CT showed moderate FDG (SUV max 5.8) uptake in a well defined soft tissue lesion posterior to the globe. The mass was seen to extend both intra and extraconally. Loss of fat planes was noted with left lateral rectus and inferior rectus. Optic nerve was not visualized separately (Figure 1). Mild to moderate FDG uptake was also noted in bilateral cervical level II, right axillary and mediastinal lymph nodes. FDG avid lesions were also noted in lung, liver bilateral adrenal glands and multiple skeletal sites which were suggestive of widespread metastatic involvement. Fine needle aspiration cytology of the left infraorbital swelling came out to be meibomian gland carcinoma. In view of widespread disseminated disease patient has been given six cycles of chemotherapy based on Injection Paclitaxel 260 mg IV day 1 and injection Cisplatin 70 mg IV day 1 at three weekly intervals. He also received palliative local radiation to left eye 30 Gray in 10 fractions over two weeks. Patient is kept on follow up and leading a good quality of life for last six months.